Biotechnological synthesis of the designer drug metabolite 4′-hydroxymethyl-α-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6 - A versatile alternative to multistep chemical synthesis

Journal of Analytical Toxicology

Volumn 33, Issue 4, 2009, Pages 190-197

  Peters, Frank T ^a   Dragan, Calin Aurel ^b   Kauffels, Anne ^a   Schwaninger, Andrea E ^a   Zapp, Josef ^c   Bureik, Matthias ^b   Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b PomBioTech GmbH   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4' HYDROXYMETHYL ALPHA PYRROLIDINOHEXANOPHENONE; CYTOCHROME P450 2D6; CYTOCHROME REDUCTASE; DESIGNER DRUG; DRUG METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; CENTRIFUGATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; FUNGUS CULTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; MASS FRAGMENTOGRAPHY; NONHUMAN; PROTEIN EXPRESSION; SCHIZOSACCHAROMYCES POMBE; SOLID PHASE EXTRACTION; SUPERNATANT; SYNTHESIS;

SCHIZOSACCHAROMYCES POMBE; SCHIZOSACCHAROMYCETACEAE;

EID: 66349096061     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/33.4.190     Document Type: Article

References (32)

1. P. Roesner, T. Junge, G. Fritschi, B. Klein, K. Thielert, and M. Kozlowski. Neue synthetische Drogen: Piperazin-, Procyclidin- und alpha-Aminopropiophenonderivate. Toxichem. Krimtech. 66: 81-90 (1999).
2. D. Springer, G. Fritschi, and H.H. Maurer. Metabolism of the new designer drug alpha-pyrrolidinopropiophenone (PPP) and the toxicological detection of PPP and 4′methyl-alpha-pyrrolidinopropiophenone (MPPP) studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796: 253-266 (2003).
3. D. Springer, F.T. Peters, G. Fritschi, and H.H. Maurer. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinopropiophenone in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 773: 25-33 (2002).
4. D. Springer, G. Fritschi, and H.H. Maurer. Metabolism and toxicological detection of the new designer drug 4′-methoxy-alpha- pyrrolidinopropiophenone studied in rat urine using gas chromatography- mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793: 331-342 (2003).
5. D. Springer, G. Fritschi, and H.H. Maurer. Metabolism and toxicological detection of the new designer drug 3′,4′-methylenedioxy- alpha-pyrrolidinopropiophenone studied in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793: 377-388 (2003).
6. F. Westphal, T. Junge, P. Rosner, G. Fritschi, B. Klein, and U. Girreser. Mass spectral and NMR spectral data of two new designer drugs with an alpha-aminophenone structure: 4′-methyl-alpha-pyrrolidinohexanophenone and 4′-methyl-alpha-pyrrolidinobutyrophenone. Forensic Sci. Int. 169: 32-42 (2007).
7. F.T. Peters, M.R. Meyer, G. Fritschi, and H.H. Maurer. Studies on the metabolism and toxicological detection of the new designer drug 4′-methyl-alpha-pyrrolidinobutyrophenone (MPBP) in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 824: 81-91 (2005).
8. D. Springer, F.T. Peters, G. Fritschi, and H.H. Maurer. New designer drug 4′-methyl-alpha-pyrrolidinohexanophenone: studies on its metabolism and toxicological detection in urine using gas chromatography-mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 789: 79-91 (2003).
9. J.P. Fauquet, E. Morel, C. Demarty, and J.R. Rapin. Role of central catecholamines in the psychostimulant activity of pyrovalerone. Arch. Int. Pharmacodyn. Ther. 224: 325-337 (1976) (in French).
10. A. Servin, J.P. Fauquet, C. Jacquot, and J.R. Rapin. Effects of pyrovalerone on peripheral noradrenergic mechanisms. Biochem. Pharmacol. 27: 1693-1694 (1978).
11. P.C. Meltzer, D. Butler, J.R. Deschamps, and B.K. Madras. 1-(4- Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. J. Med. Chem. 49: 1420-1432 (2006).
12. G. Stille, H. Ackermann, E. Eichenberger, and H. Lauener. Comparative pharmacological study of a new central stimulant, 1-p-tolyl-1-oxo-2-pyrrolidino- n-pentane HCl. Arzneimittelforschung 13: 871-877 (1963) (in German).
13. A.R. Holliday, R.B. Morris, and R.P. Sharpley. Compound 84/F 1983 compared with D-amphetamine and placebo in regard to effects on human performance. Psychopharmacologia 6: 192-200 (1964).
14. H. Heimann and G. Lukàcs. Experimental psychological differentiation of the effect of 2 psychostimulants (F-1983 and amphetamine) in humans. Psychopharmacologia 8: 79-90 (1965) (in German).
15. S. Söderholm, N.M. Viukari, and R. Rimón. The psychotropic effect of the Pyrovalerone (F-1983), placebo, the milieu therapy and mental condition of the patients in forensic psychiatry. Nervenarzt 47: 88-93 (1976) (in German).
16. J. Goldberg, G. Gardos, and J.O. Cole. A controlled evaluation of pyrovalerone in chronically fatigued volunteers. Int. Pharmacopsychiatry 8: 60-69 (1973).
17. H. Heinmann and K. Vetter. Clinical studies of a new psycho-stimulant (F-1983). Schweiz. Med. Wochenschr. 95: 306-309 (1965) (in German).
18. P. Deniker, H. Loo, H. Cuche, and J.M. Roux. Abuse of pyrovalerone by drug addicts. Ann. Med. Psychol. (Paris) 2: 745-748 (1975) (in French).
19. W. Michaelis, J.H. Russel, and O. Schindler. The metabolism of pyrovalerone hydrochloride. J. Med. Chem. 13: 497-503 (1970).
20. D.S. Lho, J. Lee, S. Kim, J. Park, and H.S. Shin. Identification of a pyrovalerone metabolite in the rat by gas chromatography-mass spectrometry and determination of pyrovalerone by gas chromatography-nitrogen-phosphorus detection. J. Chromatogr. B Biomed. Sci. Appl. 687: 253-259 (1996).
21. H.S. Shin, Y.S. Shin, S. Lee, and B.B. Park. Detection and identification of pyrovalerone and its hydroxylated metabolite in the rat. J. Anal. Toxicol. 20: 568-572 (1996).
22. H. Shin and J. Park. Identification of the new metabolites of pyrovalerone by various derivatization methods in the rat urine. Korean Biochem. J. 27: 357-361 (1994).
23. D. Springer, L.D. Paul, R.F. Staack, T. Kraemer, and H.H. Maurer. Identification of the cytochrome P450 enzymes involved in the metabolism of 4′-methyl-(alpha)-pyrrolidinopropiophenone, a novel scheduled designer drug, in human liver microsomes. Drug Metab. Dispos. 31: 979-982 (2003).
24. F.T. Peters, M.R. Meyer, D.S. Theobald, and H.H. Maurer. Identification of cytochrome P450 enzymes involved in the metabolism of 4′-methyl- pyrrolidino-butyrophenone (MPBP), a new designer drug, in human liver microsomes. Drug Metab. Dispos. 36: 163-168 (2008).
25. F.T. Peters, C.A. Dragan, D.R. Wilde, M.R. Meyer, M. Bureik, and H.H. Maurer. Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4′-hydroxymethyl-alpha-pyrrolidinobutyrophenone. Biochem. Pharmacol. 74: 511-520 (2007).
26. F.T. Peters, A.E. Schwaninger, C.-A. Dragan, M. Bureik, and H.H. Maurer. New fission yeast strains expressing human cytochrome P 450 enzymes to be used for biotechnological synthesis of drug metabolites [Abstract]. Ther. Drug Monit. 29: 466-467 (2007).
27. H.H. Maurer, K. Pfleger, and A.A. Weber. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and their Metabolites, 4th rev. ed. Wiley-VCH, Weinheim, Germany, 2007.
28. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Safety Testing of Drug Metabolites. http://www.fda.gov/CDER/GUIDANCE/ 6897fnl.pdf.
29. J. Cheng, D.F. Wan, J.R. Gu, Y. Gong, S.L. Yang, D.C. Hao, and L. Yang. Establishment of a yeast system that stably expresses human cytochrome P450 reductase: application for the study of drug metabolism of cytochrome P450s in vitro. Protein Expr. Purif. 47: 467-476 (2006).
30. M. Dietrich, L. Grundmann, K. Kurr, L. Valinotto, T. Saussele, R.D. Schmid, and S. Lange. Recombinant production of human micro somal cytochrome P450 2D6 in the methylotrophic yeast Pichia pastoris. Chembiochem. 6: 2014-2022 (2005).
31. K. Hayashi, T. Sakaki, S. Kominami, K. Inouye, and Y. Yabusaki. Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b5 in yeast. Arch. Biochem. Biophys. 381: 164-170 (2000).
32. G. Truan, C. Cullin, P. Reisdorf, P. Urban, and D. Pompon. Enhanced in vivo monooxygenase activities of mammalian P450s in engineered yeast cells producing high levels of NADPH-P450 reductase and human cytochrome b5. Gene 125: 49-55 (1993)